Ignite Creation Date:
2024-05-06 @ 4:02 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04846686
Status:
COMPLETED
Last Update Posted:
2023-07-03
First Post:
2021-04-13
Brief Title:
Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Organization:
Centre Hospitalier Universitaire de Saint Etienne
Study Overview
Official Title:
Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRE-EVE
Brief Summary:
The pathophysiology of preeclampsia PE is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors
A new angiogenic factor EG-VEGF Endocrine Gland- Derived Vascular Endothelial Growth Factor also known as Prokineticin 1 PROK1 appears to be emerging in the pathophysiology of PE EG-VEGF is a circulating factor which belongs to the family of prokinetics Dr Alfaidys MAB2 team at the Cancer and Infections Biology Laboratory U1292 Biosanté INSERM UGA CEA CEA Grenoble demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia EG -VEGF is directly involved in the development of Pre-Eclampsia Few studies have evaluated the expression of EG-VEGF in the human placenta
A new angiogenic factor EG-VEGF Endocrine Gland- Derived Vascular Endothelial Growth Factor also known as Prokineticin 1 PROK1 appears to be emerging in the pathophysiology of PE EG-VEGF is a circulating factor which belongs to the family of prokinetics Dr Alfaidys MAB2 team at the Cancer and Infections Biology Laboratory U1292 Biosanté INSERM UGA CEA CEA Grenoble demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia EG -VEGF is directly involved in the development of Pre-Eclampsia Few studies have evaluated the expression of EG-VEGF in the human placenta
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None